Resistin as a potential marker of renal disease in lupus nephritis

J. Hutcheson, Y. Ye, J. Han, C. Arriens, R. Saxena, Q. Z. Li, C. Mohan, T. Wu

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Systemic lupus erythematosus (SLE) and lupus nephritis (LN) have strong concomitance with cardiovascular disease that cannot be explained fully by typical risk factors. We examined the possibility that serum or urine expression of adipokines may act as biomarkers for LN, as these proteins have been associated previously with cardiovascular disease as well as SLE. Antibody arrays were performed on serum and urine from lupus patients and matched controls using a cross-sectional study design. From the initial array-based screening data of 15 adipokines, adiponectin, leptin and resistin were selected for validation by enzyme-linked immunosorbent assay (ELISA). Correlations were determined between adipokine expression levels and measures of disease activity or lupus nephritis. The expression of adiponectin and resistin was increased in both sera and urine from LN patients, while leptin was increased in LN patient sera, compared to matched controls. Serum resistin, but not urine resistin, was correlated with measures of renal dysfunction in LN. Serum resistin expression may be useful as a marker of renal dysfunction in patients with LN, although longitudinal studies are warranted. Further studies are necessary to determine if resistin has functional consequences in LN.

Original languageEnglish (US)
Pages (from-to)435-443
Number of pages9
JournalClinical and Experimental Immunology
Volume179
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Resistin
Lupus Nephritis
Kidney
Adipokines
Serum
Urine
Adiponectin
Leptin
Systemic Lupus Erythematosus
Cardiovascular Diseases
Longitudinal Studies
Cross-Sectional Studies
Biomarkers
Enzyme-Linked Immunosorbent Assay
Antibodies

Keywords

  • Adipokine
  • Biomarker
  • Lupus nephritis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Resistin as a potential marker of renal disease in lupus nephritis. / Hutcheson, J.; Ye, Y.; Han, J.; Arriens, C.; Saxena, R.; Li, Q. Z.; Mohan, C.; Wu, T.

In: Clinical and Experimental Immunology, Vol. 179, No. 3, 01.03.2015, p. 435-443.

Research output: Contribution to journalArticle

Hutcheson, J. ; Ye, Y. ; Han, J. ; Arriens, C. ; Saxena, R. ; Li, Q. Z. ; Mohan, C. ; Wu, T. / Resistin as a potential marker of renal disease in lupus nephritis. In: Clinical and Experimental Immunology. 2015 ; Vol. 179, No. 3. pp. 435-443.
@article{7f3096694ff7474f891857b506c1f8fb,
title = "Resistin as a potential marker of renal disease in lupus nephritis",
abstract = "Systemic lupus erythematosus (SLE) and lupus nephritis (LN) have strong concomitance with cardiovascular disease that cannot be explained fully by typical risk factors. We examined the possibility that serum or urine expression of adipokines may act as biomarkers for LN, as these proteins have been associated previously with cardiovascular disease as well as SLE. Antibody arrays were performed on serum and urine from lupus patients and matched controls using a cross-sectional study design. From the initial array-based screening data of 15 adipokines, adiponectin, leptin and resistin were selected for validation by enzyme-linked immunosorbent assay (ELISA). Correlations were determined between adipokine expression levels and measures of disease activity or lupus nephritis. The expression of adiponectin and resistin was increased in both sera and urine from LN patients, while leptin was increased in LN patient sera, compared to matched controls. Serum resistin, but not urine resistin, was correlated with measures of renal dysfunction in LN. Serum resistin expression may be useful as a marker of renal dysfunction in patients with LN, although longitudinal studies are warranted. Further studies are necessary to determine if resistin has functional consequences in LN.",
keywords = "Adipokine, Biomarker, Lupus nephritis, Systemic lupus erythematosus",
author = "J. Hutcheson and Y. Ye and J. Han and C. Arriens and R. Saxena and Li, {Q. Z.} and C. Mohan and T. Wu",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/cei.12473",
language = "English (US)",
volume = "179",
pages = "435--443",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Resistin as a potential marker of renal disease in lupus nephritis

AU - Hutcheson, J.

AU - Ye, Y.

AU - Han, J.

AU - Arriens, C.

AU - Saxena, R.

AU - Li, Q. Z.

AU - Mohan, C.

AU - Wu, T.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Systemic lupus erythematosus (SLE) and lupus nephritis (LN) have strong concomitance with cardiovascular disease that cannot be explained fully by typical risk factors. We examined the possibility that serum or urine expression of adipokines may act as biomarkers for LN, as these proteins have been associated previously with cardiovascular disease as well as SLE. Antibody arrays were performed on serum and urine from lupus patients and matched controls using a cross-sectional study design. From the initial array-based screening data of 15 adipokines, adiponectin, leptin and resistin were selected for validation by enzyme-linked immunosorbent assay (ELISA). Correlations were determined between adipokine expression levels and measures of disease activity or lupus nephritis. The expression of adiponectin and resistin was increased in both sera and urine from LN patients, while leptin was increased in LN patient sera, compared to matched controls. Serum resistin, but not urine resistin, was correlated with measures of renal dysfunction in LN. Serum resistin expression may be useful as a marker of renal dysfunction in patients with LN, although longitudinal studies are warranted. Further studies are necessary to determine if resistin has functional consequences in LN.

AB - Systemic lupus erythematosus (SLE) and lupus nephritis (LN) have strong concomitance with cardiovascular disease that cannot be explained fully by typical risk factors. We examined the possibility that serum or urine expression of adipokines may act as biomarkers for LN, as these proteins have been associated previously with cardiovascular disease as well as SLE. Antibody arrays were performed on serum and urine from lupus patients and matched controls using a cross-sectional study design. From the initial array-based screening data of 15 adipokines, adiponectin, leptin and resistin were selected for validation by enzyme-linked immunosorbent assay (ELISA). Correlations were determined between adipokine expression levels and measures of disease activity or lupus nephritis. The expression of adiponectin and resistin was increased in both sera and urine from LN patients, while leptin was increased in LN patient sera, compared to matched controls. Serum resistin, but not urine resistin, was correlated with measures of renal dysfunction in LN. Serum resistin expression may be useful as a marker of renal dysfunction in patients with LN, although longitudinal studies are warranted. Further studies are necessary to determine if resistin has functional consequences in LN.

KW - Adipokine

KW - Biomarker

KW - Lupus nephritis

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84922823828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922823828&partnerID=8YFLogxK

U2 - 10.1111/cei.12473

DO - 10.1111/cei.12473

M3 - Article

C2 - 25345756

AN - SCOPUS:84922823828

VL - 179

SP - 435

EP - 443

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -